Dapagliflozin
Brand names: Farxiga · Active ingredient: Dapagliflozin
In short: Dapagliflozin tablets are indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular (CV) disease or multiple CV risk factors. As an adjunct to diet and exercise to improve glycemic control in adults with type 2 di
What is Dapagliflozin used for?
Dapagliflozin tablets are indicated:
To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular (CV) disease or multiple CV risk factors.
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use
Dapagliflozin tablets are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus
.
Dapagliflozin tablets are not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m
2. Dapagliflozin tablets are likely to be ineffective in this setting based upon its mechanism of action.
Pediatric use information is approved for AstraZeneca AB’s Farxiga
®(dapagliflozin) Tablets. However, due to AstraZeneca AB’s marketing exclusivity rights, this drug product is not labeled with that information.
Dapagliflozin dosage
Assess renal function prior to initiation of dapagliflozin tablets and then as clinically indicated
.
Assess volume status. In patients with volume depletion, correct this condition before initiating dapagliflozin tablets
[see Warnings and Precautions (
5.2
)
and
Use in Specific Populations (
8.5
,
8.6
)]
.
Inadultswith type 2 diabetes mellitus, the recommended starting dosage of dapagliflozin tablets are 5 mg orally once daily to improve glycemic control. Foradditionalglycemic control, the dosage can be increased to 10 mg orally once daily.
For Adult Patients with Type 2 Diabetes Mellitus and Renal Impairment:
The recommended dosage for dapagliflozin tablets in patients with an eGFR greater than or equal to 45 mL/min/1.73 m
2is the same as the recommended dosage in patients with normal renal function.
Dapagliflozin tablets are not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m
2. Dapagliflozin tablets are likely to be ineffective to improve glycemic control in this setting based upon its mechanism of action.
Pediatric use information is approved for AstraZeneca AB’s Farxiga
®(dapagliflozin) Tablets. However, due to AstraZeneca AB’s marketing exclusivity rights, this drug product is not labeled with that information.
The recommended dosage of dapagliflozin tablets are 10 mg orally once daily in adults for the following indications:
To reduce the risk of hHF in patients with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.
For Adults with Renal Impairment Receiving Dapagliflozin Tablets for Indications Other than Glycemic Control:
The recommended dosage of dapagliflozin tablets in patients with an eGFR greater than or equal to 25 mL/min/1.73 m
2is the same as the recommended dosage in patients with normal renal function.
Initiation with dapagliflozin tablets are not recommended in patients with an eGFR less than 25 mL/min/1.73 m
2.
If the eGFR falls below 25 mL/min/1.73 m
2while receiving treatment with dapagliflozin tablets, patients may continue dapagliflozin tablets 10 mg orally once daily.
Withhold dapagliflozintabletsfor at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. Resume dapagliflozin tabletswhenthe patient is clinically stable and has resumed oral intake
.
If a dose is missed, instruct patients to take the dose as soon as possible.
Advise patients not to double up the next dose.
How to take Dapagliflozin — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis
In patients with type 1 diabetes mellitus, inform them that using dapagliflozin can increase their risk of life-threatening diabetic ketoacidosis. For all other patients, inform them that dapagliflozin can cause potentially fatal ketoacidosis and that type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are risk factors.
Educate all patients on precipitating factors (such as insulin dose reduction or missed insulin doses, infection, reduced caloric intake, ketogenic diet, surgery, dehydration, and alcohol abuse) and symptoms of ketoacidosis (including nausea, vomiting, abdominal pain, tiredness, and labored breathing). Inform patients that blood glucose may be normal even in the presence of ketoacidosis.
Advise patients that they may be asked to monitor ketones. If symptoms of ketoacidosis occur, instruct patients to discontinue dapagliflozin and seek medical attention immediately
. …
Warnings & precautions
Do not take this medicine if: Dapagliflozin tablets are contraindicated in patients with a history of a serious hypersensitivity reaction to dapagliflozin or any of the excipients in dapagliflozin tablets. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with dapagliflozin tablets
.
In patientswithtype 1 diabetes mellitus, dapagliflozin significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond the background rate. Inplacebo-controlled trials of patients with type 1 diabetes mellitus, the risk of ketoacidosis was markedly increased in patients who receivedsodium-glucose cotransporter 2 (SGLT2) inhibitors compared to patients who received placebo. Dapagliflozin is not indicated for glycemiccontrolin patients with type 1 diabetes mellitus.
Type 2diabetesmellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are also risk factors for ketoacidosis. There have beenpostmarketingreports of fatal events of ketoacidosis in patients with type 2 diabetes mellitus using SGLT2 inhibitors, includingdapagliflozin.
Precipitatingconditionsfor diabetic ketoacidosis or other ketoacidosis include under-insulinization due to insulin dose reduction or missed insulin doses, acute febrileillness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse.
Signs andsymptomsare consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, abdominal pain, generalized malaise,andshortness of breath. Blood glucose levels at presentation may be below those typically expected for diabetic ketoacidosis (e.g., less than 250 mg/dL).Ketoacidosisand glucosuria may persist longer than typically expected. …
Dapagliflozin side effects
The following important adverse reactions are described below and elsewhere in the labeling:
Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis
Volume Depletion
Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections
Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Dapagliflozin has been evaluated in clinical trials in adult patients with type 2 diabetes mellitus. The overall safety profile of dapagliflozin was consistent across the studied indications. Severe hypoglycemia and diabetic ketoacidosis (DKA) were observed only in patients with diabetes mellitus.
Clinical Trials for Glycemic Control in Adult Patients with Type 2 Diabetes Mellitus
Pool of 12 Placebo-Controlled Adult Trials for Dapagliflozin 5 and 10 mg for Glycemic Control
The data in Table 1 is derived from 12 glycemic control placebo-controlled trials in adult patients with type 2 diabetes mellitus ranging from 12 to 24 weeks. …
Drug interactions
Table 4: Clinically Relevant Interactions with D
apagliflozin
Insulin or Insulin Secretagogues
Clinical Impact | The risk of hypoglycemia may be increased when dapagliflozin is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea)
.
Intervention | Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia.
Lithium
Clinical Impact | Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations.
Intervention | Monitor serum lithium concentration more frequently during dapagliflozin initiation and dosage changes.
Positive Urine Glucose Test
Clinical Impact | SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests.
Intervention | Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.
Interference with 1,5-anhydroglucitol (1,5-AG) Assay
Clinical Impact | Measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors.
Intervention | Monitoring glycemic control with 1,5-AG assay is not recommended. Use alternative methods to monitor glycemic control.
About this medicine
Dapagliflozin is described chemically as D-glucitol, 1,5-anhydro-1-
C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1
S). The molecular formula is C
21H
25ClO
6and the molecular weight is 408.87. The structural formula is:
Dapagliflozin tablets are available as a film-coated tablet for oral administration containing the equivalent of 5 mg and 10 mg dapagliflozin, and the following inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose, lactose anhydrous, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80 and talc. In addition, the film coating contains the following inactive ingredients: iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
How it works: Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5dc0e9df-3b45-4469-93fe-3d2eddbfe2b7. Read the full official label on DailyMed.
Related medicines
Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro